UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date
of report (Date of earliest event reported): November 19,
2009
SKYSTAR
BIO-PHARMACEUTICAL COMPANY
(Exact
name of registrant as specified in Charter)
|
Nevada
|
|
000-28153
|
|
33-0901534
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Commission
File No.)
|
|
(IRS
Employer Identification No.)
|
Rm.
10601, Jiezuo Plaza, No.4, Fenghui Road South,
Gaoxin
District, Xi’an, Shaanxi Province
People’s
Republic of China
(Address
of Principal Executive Offices)
(8629)
8819-3188
(Issuer Telephone
Number)
N/A
(Former name or
former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Forward
Looking Statements
This Form
8-K and other reports filed by Skystar Bio-Pharmaceutical Company (the
“Registrant”) from time to time with the Securities and Exchange Commission
(collectively the “Filings”) contain forward looking statements and information
that are based upon beliefs of, and information currently available to, the
Registrant’s management as well as estimates and assumptions made by the
Registrant’s management. When used in the Filings the words
“anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the
negative of these terms and similar expressions as they relate to the Registrant
or the Registrant’s management identify forward looking
statements. Such statements reflect the current view of the
Registrant with respect to future events and are subject to risks,
uncertainties, assumptions and other factors relating to the Registrant’s
industry, operations and results of operations and any businesses that may be
acquired by the Registrant. Should one or more of these risks or
uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed,
estimated, expected, intended or planned.
Although
Registrant believes that the expectations reflected in the forward looking
statements are reasonable, Registrant cannot guarantee future results, levels of
activity, performance or achievements. Except as required by applicable law,
including the securities laws of the United States, Registrant does not intend
to update any of the forward-looking statements to conform these statements to
actual results.
|
Item
7.01
|
Regulation
FD Disclosure
|
On
September 19, 2009, the Registrant will deliver a presentation at the Brean
Murray Carret & Co. 2009 China Growth Conference in New York City. A copy of
the presentation materials used in connection with the presentation is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
The
information in this Current Report, including the presentation attached hereto
as Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be
deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that Section.
The information in the Current Report shall not be incorporated by reference
into any registration statement pursuant to the Securities Act of 1933, as
amended.
|
Item
9.01
|
Financial
Statement and Exhibits.
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
99.1
|
|
Presentation
of Skystar Bio-Pharmaceutical Company dated November 19,
2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Date:
November 19, 2009
|
Skystar
Bio-Pharmaceutical Company
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/
Bennet P. Tchaikovsky
|
|
|
Bennet
P. Tchaikovsky
|
|
|
Chief
Financial Officer
|